Uppsala, Sweden - March 22, 2016 - Orexo's Annual Report for the 2015 fiscal year has been published and can be downloaded from the investor section of the company's homepage www.orexo.com/en/Investor-Relations/.

For further information, please contact:
Lena Wange, IR & Communications Manager
Tel: +46 (0)18-780 88 00, E-mail: ir@orexo.com

About Orexo
 Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for maintenance treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO:ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden.

For information about Orexo please visit www.orexo.com.

The following files are available for download:

Orexo AB issued this content on 22 March 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 22 March 2016 10:53:16 UTC

Original Document: http://www.orexo.com/en/Investor-Relations/Press-releases/?guid=1125322